GlassScriptPhysician profile
Lee Michael Gerwitz
NPI 1972921591
$87,819.99
in general payments reported to CMS, 2019-2025
22 companies · $60K in 2025
The $60K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $172 · 2021: $1,341 · 2022: $2,923 · 2023: $7,118 · 2024: $16K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Consulting Fee: $18K · Food and Beverage: $15K · Travel and Lodging: $7,308 · Education: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,994.00 |
| Consulting Fee | $18,287.50 |
| Food and Beverage | $14,784.65 |
| Travel and Lodging | $7,307.75 |
| Education | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $36,180.86 | 2021-2025 | Mavenclad, Mavenclad |
| Amgen INC. | $27,111.43 | 2024-2025 | Uplizna |
| Genentech USA, INC. | $6,073.12 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Genzyme Corporation | $3,471.03 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $3,304.69 | 2020-2025 | Kesimpta |
| Alexion Pharmaceuticals, INC. | $3,230.42 | 2022-2025 | Ultomiris, Soliris |
| Tg Therapeutics, INC. | $2,668.70 | 2023-2025 | |
| Biogen, INC. | $1,376.78 | 2021-2025 | Vumerity, Tysabri |
| Abbvie INC. | $1,092.86 | 2024-2025 | |
| Pfizer INC. | $1,049.55 | 2023-2025 | |
| Celgene Corporation | $995.96 | 2021-2025 | Zeposia |
| Horizon Therapeutics Plc | $348.96 | 2022-2023 | Uplizna |
| Janssen Pharmaceuticals, INC | $217.63 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $186.28 | 2025 | Ajovy |
| Banner Life Sciences, LLC | $165.18 | 2021-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $110.17 | 2022 | |
| Allergan, INC. | $82.91 | 2020-2022 | |
| Genentech, INC. | $68.85 | 2022 | |
| Argenx US, INC. | $29.32 | 2023 | Vyvgart Hytrulo |
| Merz Pharmaceuticals, LLC | $24.50 | 2023 | Xeomin |
| Catalyst Pharmaceuticals, INC. | $15.72 | 2021 | |
| Sk Life Science, INC. | $15.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Gerwitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.